Bendamustine-d4 hydrochloride(Synonyms: 盐酸苯达莫司汀 d4 (盐酸盐))


Bendamustine-d4 hydrochloride (Synonyms: 盐酸苯达莫司汀 d4 (盐酸盐))

Bendamustine-d4 hydrochloride 是 Bendamustine hydrochloride 的氘代物。Bendamustine hydrochloride (SDX-105),一种嘌呤类似物,是一种 DNA 交联剂。Bendamustine hydrochloride 可激活 DNA 损伤反应和细胞凋亡 (apoptosis)。Bendamustine hydrochloride 具有有效的烷基化,抗癌和抗代谢作用。

Bendamustine-d4 hydrochloride(Synonyms: 盐酸苯达莫司汀 d4 (盐酸盐))

Bendamustine-d4 hydrochloride Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.


Bendamustine-d4 hydrochloride is the deuterium labeled Bendamustine hydrochloride. Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1].

(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.






盐酸苯达莫司汀 d4 (盐酸盐)


Room temperature in continental US; may vary elsewhere.


Please store the product under the recommended conditions in the Certificate of Analysis.

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17.

    [3]. Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17.

    [4]. Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin’s lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91.